aTyr Pharma
ATYR
37 hedge funds and large institutions have $72.8M invested in aTyr Pharma in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 10 closing their positions.
214% more call options, than puts
Call options by funds: $22K | Put options by funds: $7K
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
83% more capital invested
Capital invested by funds: $39.8M → $72.8M (+$33M)
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
6% more funds holding
Funds holding: 35 → 37 (+2)
2.62% more ownership
Funds ownership: 62.59% → 65.21% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$10.9M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$10.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.94M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$3.83M |
| 5 |
TM
Tikvah Management
Charlotte,
North Carolina
|
+$2.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$2.57M |
| 2 |
Walleye Capital
New York
|
-$1.64M |
| 3 |
Citigroup
New York
|
-$938K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$283K |
| 5 |
Millennium Management
New York
|
-$149K |
ATYR Hedge Fund Activity: Q1 2023 in Review
37 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2023, worth a combined $72.8M — up 83% from $39.8M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ATYR positions and 10 closed out — a net gain of 3 holders — while 13 added to existing stakes and 6 trimmed.
The largest buyer was Federated Hermes, adding an estimated $10.9M. The largest seller was VR Adviser, exiting entirely with an estimated $2.57M sold.
- 37 institutional investors held aTyr Pharma (ATYR) as of Q1 2023, up from 35 in Q4 2022.
- Funds reported $72.8M of aTyr Pharma stock for Q1 2023, up 83% quarter-over-quarter.
- 13 funds opened new aTyr Pharma positions in Q1 2023 and 10 closed out, a net change of +3 holders.
- The largest aTyr Pharma buyer in Q1 2023 was Federated Hermes, an estimated $10.9M added.
- The largest aTyr Pharma seller in Q1 2023 was VR Adviser, an estimated $2.57M sold.
Based on aggregated 13F filings for Q1 2023.